Commercialisation of research output

AMBER researchers are committed to continuing to perform commercially relevant research. Our researchers have filed 154 invention disclosures, 94 patents, and signed 32 licenses or assignments of IP to companies.

AMBER continues to develop technologies to bring them closer to commercialisation. AMBER PI Prof Bruce Murphy has spun out SELIO Medical is focused on the development of a medical device to prevent pneumothorax during transthoracic needle biopsy. Our second spin out Senoptica is focusing on developing integrity indicators for smart packaging. All of these technologies received EI Commercialisation funding. We also see exciting potential, through the Horizon Europe EIC pillar, to develop some of our ERC PoC research further to market, ultimately to licensing and spin-out, via the Transition and Accelerator programmes.